Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk

NCT07619495 · Completed

Last updated 2026-07-12

This clinical trial compares two injectable medications, semaglutide and dulaglutide, in adults with type 2 diabetes, obesity, or overweight who are at risk for heart disease to see which one may better prevent heart-related events.

Status Completed The study has finished.

Type Observational

Participants 120,000 people

Who can join Ages 18+ · all sexes

Timeline Started 2026-01 · est. completion 2026-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07619495 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

Semaglutide Drug

Initiation of injectable semaglutide described in electronic health records is used as the exposure.
Dulaglutide Drug

Initiation of dulaglutide described in electronic health records is used as the reference.

Main thing measured	Composite of all-cause mortality, myocardial infarction, or stroke.
Sponsor	Brigham and Women's Hospital
Conditions studied	Type 2 Diabetes Mellitus, Obesity, Overweight
GLP-1 drugs	semaglutide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07619495 ↗